कंपनी का अवलोकन
Innate Pharma S.A. operates as a biotechnology firm focused on developing immunotherapies specifically designed for cancer patients within the French and international markets. The company's portfolio includes Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently undergoing Phase II clinical trials for the treatment of cutaneous T-cell leukemia and peripheral T-cell lymphoma. This enterprise functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning it as a developer of novel biological treatments rather than a manufacturer of generic pharmaceuticals. With a market capitalization of $136.00M, annual revenue of $9.01M, and an employee base of 163, the organization represents a micro-cap entity with significant operational constraints typical of early-stage biotech firms. These financial dimensions indicate that the company maintains a very small scale relative to large-cap pharmaceutical peers, relying heavily on the successful progression of its clinical pipeline to generate future value rather than established commercial revenue streams.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $9.01M alongside a net income of -$49,177,000 and an EBITDA of -$52,625,000, highlighting a severe structural deficit where costs substantially exceed generated income. This massive negative gap between revenue and net income reveals an operating model driven by high research and development expenditures that are not yet offset by commercial sales. The firm holds $34.31M in cash against $22.57M in debt, providing a net cash position that offers some liquidity buffer despite the ongoing financial bleed. The balance sheet is technically conservative regarding leverage since the company possesses more liquid assets than debt obligations, yet the negative earnings erode equity over time. The current ratio stands at 1.27, indicating that for every dollar of current liabilities, the company holds $1.27 in current assets, which suggests adequate short-term liquidity to meet immediate obligations. The gross margin is 0.0%, the operating margin is -689.6%, and the profit margin is 0.0%, all figures reflecting the pre-revenue or low-revenue stage where fixed costs dominate the income statement. Return on Equity is N/A due to negative equity, while the Return on Assets stands at -38.8%, demonstrating that management is currently destroying asset value rather than generating returns on the capital deployed.
मूल्यांकन आकलन
The trailing P/E ratio is N/A because the company has no earnings, while the forward P/E is listed as -2.31, a negative figure that implies the market prices the stock based on future earnings potential rather than historical profitability. The price-to-book ratio is -5.33, indicating that the market values the company at a negative multiple of its book value, a common characteristic for biotech firms with significant intangible assets or R&D liabilities not fully reflected on the balance sheet. The price-to-sales ratio is 15.10, suggesting investors are willing to pay a premium of 15 times current revenue for the intellectual property and clinical trial assets associated with the firm. The EV/EBITDA multiple is -2.36, further emphasizing that traditional valuation metrics are distorted by the company's lack of profitability and high cash burn rates. Regarding price metrics, the 52-week high is $2.63 and the 52-week low is $1.17, meaning the stock trades within a range of over $1.46 per share. The beta value is 0.74, which indicates that the stock's price volatility is approximately 26% lower than the broader market, suggesting a defensive correlation relative to the S&P 500 despite the high-risk nature of the biotechnology sector.
Growth & Income
The revenue growth year-over-year is -46.7%, while earnings growth is N/A, illustrating a contraction in top-line sales that is exacerbated by rising operational costs and lack of profit generation. The negative revenue growth implies that the company is failing to expand its commercial footprint or is experiencing a decline in sales of existing products, a critical concern for a firm dependent on market traction. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all available capital. This strategy of reinvesting earnings into growth is standard for biotech firms attempting to fund clinical trials and regulatory approvals rather than returning cash to investors. The overall growth and income profile is characterized by significant headwinds in revenue contraction, a complete absence of current profitability, and a reliance on cash reserves to fund future development activities without generating shareholder returns through dividends.